FEM1C: A Potential Drug Target for Cancer and Cell Division Regulation
FEM1C: A Potential Drug Target for Cancer and Cell Division Regulation
FEM1C, also known as EUROIMAGE686608, is a protein that is expressed in various tissues throughout the body. It is a key regulator of cell division and has been implicated in the development and progression of various diseases, including cancer.
One of the most promising aspects of FEM1C is its potential as a drug target. Its role in cell division and its involvement in disease have made it an attractive target for researchers to explore for new treatments.
FEM1C has been shown to play a crucial role in the regulation of cell division and cell signaling. It is a key regulator of the cyclin D1-CDK4 complex, which is responsible for regulating cell division and cell signaling. This complex is composed of several proteins, including CDK4, which is a key regulator of cell growth and cell cycle progression, and p21, which is a tumor suppressor protein that helps to prevent the formation of cancer cells.
Research has shown that FEM1C plays a key role in the regulation of cell division and cell signaling by controlling the activity of the cyclin D1 protein. Cyclin D1 is a protein that is involved in cell division and cell signaling. It has been shown to play a crucial role in the regulation of cell growth, cell cycle progression, and the formation of cancer cells.
FEM1C has also been shown to regulate the activity of the CDK4 protein, which is a key regulator of cell growth and cell cycle progression. CDK4 is a protein that is involved in the regulation of cell growth, cell cycle progression, and the formation of cancer cells.
In addition to its role in cell division and cell signaling, FEM1C has also been shown to play a key role in the regulation of cell adhesion and tissue structure. It is a protein that is involved in the regulation of cell adhesion and in the formation of tissues and organs.
FEM1C is also involved in the regulation of cell migration and the formation of tissues and organs. It is a protein that is involved in the regulation of cell migration and the formation of tissues and organs, which is essential for the development and maintenance of tissues and organs.
In conclusion, FEM1C is a protein that is involved in the regulation of cell division, cell signaling, cell adhesion, and tissue structure. Its role in these processes makes it an attractive target for drug development. Further research is needed to fully understand the role of FEM1C in disease and to develop new treatments.
Protein Name: Fem-1 Homolog C
Functions: Substrate-recognition component of a Cul2-RING (CRL2) E3 ubiquitin-protein ligase complex of the DesCEND (destruction via C-end degrons) pathway, which recognizes a C-degron located at the extreme C terminus of target proteins, leading to their ubiquitination and degradation (PubMed:29779948, PubMed:29775578, PubMed:33398170, PubMed:33398168). The C-degron recognized by the DesCEND pathway is usually a motif of less than ten residues and can be present in full-length proteins, truncated proteins or proteolytically cleaved forms (PubMed:29779948, PubMed:29775578, PubMed:33398170, PubMed:33398168). The CRL2(FEM1C) complex specifically recognizes proteins with an arginine at the C-terminus: recognizes and binds proteins ending with -Lys/Arg-Xaa-Arg and -Lys/Arg-Xaa-Xaa-Arg C-degrons, such as SIL1 or OR51B2, leading to their ubiquitination and degradation (PubMed:33398170, PubMed:33398168). The CRL2(FEM1C) complex mediates ubiquitination and degradation of truncated MSRB1/SEPX1 selenoproteins produced by failed UGA/Sec decoding (PubMed:26138980). Promotes ubiquitination and degradation of SLBP (PubMed:28118078)
The "FEM1C Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about FEM1C comprehensively, including but not limited to:
• general information;
• protein structure and compound binding;
• protein biological mechanisms;
• its importance;
• the target screening and validation;
• expression level;
• disease relevance;
• drug resistance;
• related combination drugs;
• pharmacochemistry experiments;
• related patent analysis;
• advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai
More Common Targets
FEN1 | FENDRR | FER | FER1L4 | FER1L5 | FER1L6 | FER1L6-AS1 | FER1L6-AS2 | FERD3L | FERMT1 | FERMT2 | FERMT3 | Ferritin | FES | Fetal Hemoglobin (HbF) | FETUB | FEV | FEZ1 | FEZ2 | FEZF1 | FEZF1-AS1 | FEZF2 | FFAR1 | FFAR2 | FFAR3 | FFAR4 | FGA | FGB | FGD1 | FGD2 | FGD3 | FGD4 | FGD5 | FGD5-AS1 | FGD5P1 | FGD6 | FGF1 | FGF10 | FGF10-AS1 | FGF11 | FGF12 | FGF12-AS2 | FGF13 | FGF13-AS1 | FGF14 | FGF14-AS1 | FGF14-AS2 | FGF14-IT1 | FGF16 | FGF17 | FGF18 | FGF19 | FGF2 | FGF20 | FGF21 | FGF22 | FGF23 | FGF3 | FGF4 | FGF5 | FGF6 | FGF7 | FGF7P3 | FGF7P5 | FGF7P6 | FGF8 | FGF9 | FGFBP1 | FGFBP2 | FGFBP3 | FGFR1 | FGFR1OP2 | FGFR2 | FGFR3 | FGFR3P1 | FGFR4 | FGFRL1 | FGG | FGGY | FGL1 | FGL2 | FGR | FH | FHAD1 | FHDC1 | FHF Complex | FHIP1A | FHIP1B | FHIP2A | FHIP2B | FHIT | FHL1 | FHL2 | FHL3 | FHL5 | FHOD1 | FHOD3 | FIBCD1 | FIBIN | FIBP
